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Retroviruses have distinct preferences in integration site selection in the host cell genome during in vitro
infection, with human immunodeficiency virus type 1 (HIV-1) integration strongly favoring transcriptional
units. Additionally, studies with HIV-1 have shown that the genomic site of proviral integration may impact
viral replication, with integration in heterochromatin associated with a block in viral transcription. HIV-2 is
less pathogenic than HIV-1 and is believed to have a lower replication rate in vivo. Although differences in
integration site selection between HIV-2 and HIV-1 could potentially explain the attenuated pathogenicity of
HIV-2, no studies have characterized integration site selection by HIV-2. In this study, we mapped 202 HIV-2
integration sites during in vitro infection of peripheral blood mononuclear cells with a primary HIV-2 isolate.
In addition, we assayed for in vivo proviral integration within heterochromatin in 21 HIV-1-infected subjects
and 23 HIV-2-infected subjects, using an alphoid repeat PCR assay. During in vitro infection, HIV-2 displayed
integration site preferences similar to those previously reported for HIV-1. Notably, 82% of HIV-2 integrations
mapped to Refseq genes, and integration strongly favored regions of the genome with high gene density and
high GC content. Though rare, the proportion of HIV-2 subjects with evidence of proviral integration within
heterochromatin in vivo was higher than that of HIV-1-infected subjects. It is therefore possible that integra-
tion site selection may play a role in the differences in HIV-1 and HIV-2 in vivo pathogenesis.
Integration of proviral DNA into the host cell genome is
catalyzed by the viral integrase protein and is necessary for
replication of retroviruses (14). Although integration site se-
lection does not occur in a sequence-specific manner, recent
studies have indicated that retrovirus integration favors palin-
dromic sequences and that distinct genomic sequences are
favored in a retrovirus species-specific manner (15, 42). At the
genomic level, it is now clear that retroviruses have discrete
preferences in integration site selection. For instance, studies
have shown that during in vitro infection, human immunode-
ficiency virus type 1 (HIV-1) has a preference for proviral
integration into coding regions of the genome and in actively
transcribed host genes (27, 34). Simian immunodeficiency
virus (SIV) has been shown to have a similar preference for
integration site selection, both in cell lines and in hemato-
poietic stem cells of rhesus monkeys (10, 13). In contrast,
murine leukemia virus (MLV) integration has a preference
for integration near the start of transcriptional units and in
close proximity to CpG islands (27, 41). Finally, integration
site selection for avian sarcoma-leukosis virus (ASLV) has
been shown to be the closest to random, with only a minor
preference for integration in transcriptional units during
infection in both human cell lines (27, 28) and chicken
embryo fibroblasts (4).
Human immunodeficiency virus type 2 (HIV-2) is a lentivi-
rus closely related to SIV and more distantly related to HIV-1.
Like HIV-1, HIV-2 causes AIDS in humans. However, disease
progression occurs much more slowly in HIV-2 infection, and
spread of the virus is primarily limited to West Africa (19, 25,
26, 40). Previous studies have shown that proviral loads are
similar between people infected with HIV-1 and those with
HIV-2 (5, 29, 30). In contrast, plasma viral loads are signifi-
cantly higher in people infected with HIV-1 (1, 2, 30, 31, 36).
Based on these findings, it has been suggested that viral rep-
lication rates are lower in people infected with HIV-2 than in
people infected with HIV-1 (30).
In people infected with HIV-1, a subset of infected cells have
integrated proviral genomes that fail to undergo replication
(23). Studies in vitro have shown that a small proportion of
cells infected by HIV-1 develop a similar latent state, with the
absence of transcription driven from the viral promoter in
nonstimulated cells (16, 17). Importantly, within these cells,
viral integration occurs commonly within or close to alphoid
repeats in heterochromatin. In contrast, integration in hetero-
chromatin is disfavored in cells that had active transcription
from the viral promoter, suggesting that the genomic site of
proviral integration may affect viral replication (16). Similarly,
a recent integration mapping study found that the genomic site
of HIV-1 integration has a major effect on viral transcription,
and low viral transcription is associated with integration in
gene deserts, centromeric heterochromatin, and very highly
expressed genes (24).
These studies underscore the effect that integration site se-
lection has on retroviral replication. No studies to date have
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examined integration site selection by HIV-2. In order to char-
acterize integration site selection by HIV-2, we infected pri-
mary peripheral blood mononuclear cells (PBMCs) with a pri-
mary HIV-2 isolate and mapped 202 integration sites within
the human genome. To examine if integration site selection
may account for differences between HIV-1 and HIV-2 in in
vivo viral replication, we assayed for the presence of proviral
integration within heterochromatin in PBMCs of people in-
fected with HIV-1 and people infected with HIV-2.
MATERIALS AND METHODS
Sample acquisition. PBMC samples were obtained from a cohort of registered
female sex workers in Dakar, Senegal, that have been followed since 1985.
Informed consent was obtained for all study participants. Epidemiologic and
clinical aspects of this cohort have been described previously (18). CD4 T-cell
counts were determined, and serum samples were diagnosed for HIV-1- and
HIV-2-specific antibodies as described previously (18). DNA was extracted from
PBMC samples (Blood and Cell Culture DNA Midi kit; QIAGEN, Valencia,
CA) and resuspended in 125 l H20. DNA concentrations were determined by
optical density readings at 260 nm.
In vitro viral infection. The HIV-2 viral strain used in this study (p1629) was
previously isolated from a subject from our female sex worker cohort (18). For
infection, PBMCs from a normal U.S. blood donor were separated and stimu-
lated for 72 h with 5 g/ml phytohemagglutinin in complete interleukin 2 (IL-2)
medium (RPMI medium 1640 supplemented with 20% [vol/vol] fetal bovine
serum, 1% antibiotics, and 50 units/ml IL-2), as previously described (21).
Phytohemagglutinin was removed, and cells were infected with p1629 at a
high multiplicity of infection. Twenty-four hours postinfection, cells were
washed to remove residual supernatant virus and resuspended in fresh com-
plete IL-2 medium.
Sequencing of HIV-2 integration sites. A library of DNA fragments containing
the terminal 5 end of integrated HIV-2 long terminal repeat (LTR) and up-
stream human genomic DNA corresponding to the integration site junction was
created by linker-mediated nested PCR, using the Universal Genome Walker kit
(BD Biosciences Clontech, Palo Alto, CA), according to the manufacturer’s
recommendations, with modifications described below. Two micrograms of DNA
extracted 7 days postinfection was digested with DraI in a 20-l reaction at 37°C
for 12 h and inactivated by incubation at 65°C for 20 min. Digested DNA was
ligated to an adaptor provided by the manufacturer in a 40-l reaction at 16°C
for 12 h and inactivated by incubation at 70°C for 5 min. Sequences specific to the
viral integration site junction were amplified in a nested PCR using the adaptor-
specific primers AP1 and AP2 provided by the manufacturer and HIV-2-specific
primers link1 (TCCTGCCGCCCTTACTGCCTTCACTCA) and link2 (GGTA
CCTTACTCCTGGCCCATGAGTATA) for the first- and second-round PCRs,
respectively, using commercially available PCR reagents (BD Advantage 2 PCR
kit; BD Biosciences Clontech, Palo Alto, CA). The first-round PCR was per-
formed at a volume of 100 l, and 2 l of the first round product was used in the
second-round PCR in a volume of 50 l. Both PCRs were performed under the
following reaction conditions: 7 cycles of 94°C for 25 s and 72°C for 3 min; 32
cycles of 94°C for 25 s and 67°C for 3 min; 7-min extension at 67°C. Amplified
products were cloned into an expression vector (pCR2.1; Invitrogen, Carlsbad,
CA), and transformed into competent cells (TOP10; Invitrogen, Carlsbad, CA).
Individual colonies were selected; cloned plasmids were purified (SNAP Mini-
Prep kit; Invitrogen, Carlsbad, CA) and sequenced using M13 primers (Invitro-
gen, Carlsbad, CA).
Mapping integration sites. The BLAT program (University of California,
Santa Cruz, Human Genome Project working draft May 2004 freeze; http://www
.genome.ucsc.edu/) (20) was used to map integration sites. Sequences that met
the following criteria were considered authentic integration sites: (i) contained
the terminal 5 end of the HIV-2 LTR; (ii) had matching genomic DNA within
five bp of the end of the viral LTR; (iii) had at least 95% homology to human
genomic sequence across the entire sequenced region; (iv) matched a single
human genetic locus with at least 95% homology across the entire sequenced
region. A total of 202 sequences met the above criteria and were used in this
study.
Development of real-time PCR standards. A 292-bp fragment containing a
portion of the HIV-1 LTR and gag gene was amplified from DNA of a patient
infected with HIV-1 subtype A in a heminested PCR using the first-round
primers AM1LTRsd (CCTCAATAAAGCTTGCCTTGAG) and G75 (CTTCT
ATTACTTTTACCCATGC) and second-round primers AM1LTRsd and
AM1C1r (CTTAATACTGACGCTCTCGCACCC). A 307-bp fragment of the
HIV-2 LTR was amplified from a previously cloned HIV-2 DNA sample in a
single-round PCR using the primers AM2LTRsd (TCTGTATAAATGTACCC
GCTT) and AM2C1r (AAGGGTCCTAACAGACCAGGGTCT). The HIV-1
and HIV-2 amplicons were cloned into an expression vector (pCR2.1; Invitrogen,
Carlsbad, CA) and transformed into competent cells (TOP10; Invitrogen, Carls-
bad, CA). Cloned plasmids were purified (SNAP MiniPrep kit; Invitrogen, Carls-
bad, CA), and concentrations of purified plasmids were determined by optical
density readings at 260 nm.
Quantification of proviral load. The Applied Biosystems Taqman model 7000
thermocycler and a standardized master mix containing buffer, nucleotides, and
enzyme (Taqman Universal PCR Master Mix; Applied Biosystems, Foster City,
CA) were used for all real-time PCRs. For quantification of HIV-1 samples, a
158-bp fragment containing a portion of the HIV-1 LTR and gag gene was
amplified using primers AM1C2f (ATCTCTAGCAGTGGCGCCCGA) and
AM1C2r (CCTTCTAGCCTCCGCTAGTCA) and detected using the probe
INT-1 (ACGCAGGACTCGGCTTGCTG). For quantification of HIV-2 sam-
ples, a 155-bp fragment of the HIV-2 LTR was amplified using primers AM2C2f
(GCAGGTAGAGCCTGGGTGTTC) and AM2C2r (CAGGCGGCGACTAG
GAGAGAT) and detected using the probe INT-2 (AGACGGCTCCACGCTT
GCTT). Both probes contained a 5 6-carboxyfluorescein fluorescent reporter
and a 3 MGB nonfluorescent quencher. Twenty picomoles of each primer and
10 picomoles of probe were used for the respective HIV-1 and HIV-2 real-time
PCRs, and all reactions were performed in a final volume of 50 l. PCR condi-
tions for both HIV-1 and HIV-2 were as follows: initial incubation at 50°C for 2
min; denaturation at 94°C for 5 min; and 45 PCR cycles of 95°C for 15 s and 60°C
for 1 min. New HIV-1 and HIV-2 standards were made for each real-time PCR
run from stock aliquots at a concentration of 105 copies/l and were diluted by
10-fold serial dilutions in HIV-negative human DNA at a concentration of 10
ng/l. Ten microliters of standard was used for each real-time PCR run, and
standards were used in triplicate. For PBMC samples, 1 g of extracted DNA
was used to quantify the proviral load, and reactions were performed in dupli-
cate. Because of differences in the lengths of the HIV-1 and HIV-2 LTR regions,
the real-time PCR assay for HIV-1 used a 5 primer specific to the viral LTR and
a 3 primer specific to the viral gag gene, which amplified a single fragment within
the viral genome, whereas both primers for the HIV-2 real-time PCR assay were
specific to the viral LTR. Since proviral DNA contains copies of the LTR on both
ends of the viral genome, the actual HIV-2 proviral load was determined by
dividing by 2 the proviral load quantified using real-time PCR.
Detection of proviral integration in heterochromatin in vivo by alphoid repeat
PCR. To assay for proviral integration within heterochromatin, we modified an
assay described previously (16) that uses PCR to selectively amplify proviral
sequences within or near alphoid repeats, using a virus-specific primer and
primers designed to alphoid repeat consensus sequence. Alphoid repeats are
highly enriched within heterochromatin (33). For the PCR, we used the alphoid
repeat primers 1 (AGACAGAAGCATTCTSAGAA) and 4 (AAAGAGTGT
TTCMAANCTGCTCW) (16), which amplify in opposite directions within
alphoid repeats, to maximize the likelihood of detecting proviral DNA, and the
viral primers AM1C1r (CTTAATACTGACGCTCTCGCACCC) and AM2C1r
(AAGGGTCCTAACAGACCAGGGTCT) for HIV-1-infected and HIV-2-in-
fected subjects, respectively. PCR amplification was performed in a 50-l, 40-
cycle PCR using 1 g of DNA under reaction conditions described previously
(16). The amount of proviral sequence amplified by alphoid repeat-specific PCR
was quantified by real-time PCR using 5 l of amplified product in duplicate, as
described above. Samples with proviral sequence amplified at least 10 times
relative to the amount of nonamplified proviral DNA carryover from the alphoid
repeat-specific PCR were defined as being positive for the presence of proviral
integration within heterochromatin.
Nucleotide sequence accession numbers. Nucleotide sequences of integration
site junctions were deposited in GenBank (accession numbers DQ632388 to
DQ632563).
RESULTS
Genomic features of HIV-2 integration site selection. HIV-1
integration strongly favors transcriptional units (27, 34). We
assessed the tendency of HIV-2 to integrate within transcrip-
tional units by measuring the proportion of HIV-2 integrations
occurring in Refseq genes. Refseq genes represent a nonre-
dundant collection of transcripts that are collected on the basis
of known mRNA transcripts and manually curated to ensure
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accuracy (32). At the time of our analysis, 24,722 Refseq genes
had been identified within the human genome, accounting for
35.9% of the human genome. Of 202 HIV-2 integration sites
mapped, 166 landed with Refseq genes (82.2%) (Table 1), a
proportion much higher than expected by chance (P 0.0001).
Interestingly, we noted that among integration sites within
Refseq genes, a high proportion of HIV-2 genomes integrated
in the reverse direction relative to the direction of transcription
(60.1%; P  0.0122). This finding contrasts with findings for
HIV-1, which has been reported to have no bias in the direc-
tion of integration (34).
CpG islands are regions of the genome enriched in the rare
CpG dinucleotide and are commonly located near transcrip-
tional start sites. MLV has been shown to have a strong ten-
dency towards integration near CpG islands and near sites of
transcriptional initiation (27, 41). Of the HIV-2 integration
sites mapped, 2.0% were within 1 kb of a CpG island. As a
comparison, previous simulations have estimated 2.1% of ran-
dom integrations to fall within 1 kb of a CpG island in the
human genome (41), which is not statistically different from
the proportion observed for HIV-2 (P  0.9055). In order to
examine HIV-2 integration near transcriptional start sites, the
proportion of integrations expected to randomly land within 5
kb of a transcriptional start site based on a simulation pub-
lished by Wu et al. (41) were extrapolated to correct for in-
creased numbers of Refseq transcripts at the time of this anal-
ysis, as described previously (28). The proportion of HIV-2
integrations located within 5 kb of transcriptional start sites
was significantly higher than expected for random integration
(16.3%; P 0.0001); however, this tendency was not as high as
previously reported for MLV (27, 41). Because HIV-2 did not
have a bias in integration near CpG islands, the high propor-
tion of HIV-2 integrations near transcription start sites is likely
due to the strong preference of HIV-2 for integration within
transcriptional units and not due to a direct tendency toward
integration near transcriptional start sites.
We examined the GC content in the flanking 1-Mb window
(500 kb from the integration site) surrounding each integra-
tion site. The mean GC content in this window was 44.6%, a
value significantly higher than expected by chance (P 
0.0001). Similarly, the average gene density (the percentage of
bases that are in Refseq genes) in the 1-Mb window surround-
ing each integration site was 51.2%, which was higher (P 
0.0001) than the overall gene density of the human genome.
Repetitive elements account for close to half of the sequence
in the human genome (22), with the majority falling into four
classes of transposable elements: short interspersed elements
(SINEs), long interspersed elements (LINEs), LTR elements,
and DNA elements (3, 37). Compared to the proportion of the
genome represented by SINEs, HIV-2 had a significantly in-
creased probability for integration within SINEs (25.5%; P 
0.0001) (Table 2), as well as integration within Alu elements,
the most common type of SINE (22.3%; P  0.0001). Con-
versely, integration by HIV-2 was disfavored within LINEs
(10.9%; P  0.0004) as well as within LTR elements (3.0%;
P  0.0038). The proportion of HIV-2 integrations within
DNA elements did not differ statistically from the proportion
of the genome (5.0%; P  0.1065). Other repetitive elements
represent a minor proportion of overall genomic sequence,
and we did not observe a significant number of HIV-2 integra-
tions within any other repetitive elements. Of note, alphoid
repeats are highly enriched in heterochromatin (35). Of 202
HIV-2 integration sites mapped during in vitro infection, no
integrations occurred within alphoid repeats.
Integration of proviral DNA within heterochromatin in vivo.
Integration of HIV-1 within heterochromatin can result in a
block in viral transcription (16, 24); however, integration
within heterochromatin is a rare event during in vitro HIV-1
infection (7, 34). In this study, similar results were observed
during in vitro HIV-2 infection. In order to assay for evidence
of in vivo viral integration within heterochromatin, we modi-
fied a previously described alphoid repeat PCR assay (16) that
amplifies proviral DNA through the use of a virus-specific
primer and primers specific to alphoid repeats. To avoid study
bias due to unequal amplification between HIV-1 and HIV-2
samples, we used virus-specific reverse primers for HIV-1 and
HIV-2 that were located equal distances from the 5 end of the
respective viral genomes and were previously observed to ef-
fectively amplify integrated proviral DNA (P. Kanki, unpub-
lished observations). We assayed for the presence of proviral
integration in heterochromatin in PBMC DNA samples from
TABLE 1. Characteristics of HIV-2 integration sites and
comparison with the human genomea
Parameter
Value for
HIV-2
integrations
Value for
human
genome
P value f
% Located:
Within transcriptional unitb 82.2 35.9 0.0001
Within 1 kb of a CpG island 2.0 2.1d 0.9055
Within 5 kb of a
transcriptional start siteb
16.3 5.9e 0.0001
GC content (%) in flanking
1-Mb window
44.6 40.9 0.0001
Gene density (%) in flanking
1-Mb windowc
51.2 35.9 0.0001
a Two hundred two HIV-2 integration sites were analyzed. Human genome
data are from the Human Genome Project working draft May 2004 freeze
(http://www.genome.ucsc.edu/).
b Transcriptional units are Refseq genes.
c Gene density is defined as the percentage of overall bases falling within
Refseq genes.
d Data from simulation of random integrations by Wu et al. (41).
e Expected value from simulation of random integrations by Wu et al. (41),
extrapolated to correct for increased numbers of Refseq transcripts.
f P value for 2 test for difference in proportions between HIV-2 integrations
and the human genome.
TABLE 2. Percentages of HIV-2 integrations within repetitive
elements and percentages observed in the human genomea
Repetitive
element
% of HIV-2
integrations
% of human
genome P value
b
SINE 25.3 13.7 0.0001
Alu element 22.3 10.8 0.0001
LINE 10.9 21.1 0.0004
LTR 3.0 8.7 0.0038
DNA 5.0 3.0 0.1065
a Two hundred two HIV-2 integrations were analyzed. Percentages of repet-
itive elements in the human genome are taken from the Human Genome Project
working draft May 2004 freeze (http://www.genome.ucsc.edu/).
b P value for 2 test for difference in proportions between HIV-2 integrations
and the human genome.
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21 HIV-1-infected and 23 HIV-2-infected subjects. All subjects
were antiretroviral therapy naive and had detectable proviral
loads. There was no difference in mean CD4 T-cell counts or
mean proviral loads between subjects infected with HIV-1 and
those with HIV-2. Proviral integration in heterochromatin was
detected in 0 of 21 HIV-1-infected subjects and 5 of 23 HIV-2-
infected subjects (Table 3). Although integration within hetero-
chromatin was not detected for the majority of HIV-2-infected
subjects, the proportion testing positive was statistically higher
than that of HIV-1-infected subjects (Fisher’s exact test; two-
sided P value  0.0497).
DISCUSSION
HIV-2 has been shown to be less pathogenic and is believed
to have a lower in vivo rate of replication than HIV-1. Studies
with HIV-1 have shown that integration site selection has an
effect on viral transcription (16, 24) and possibly viral replica-
tion. To examine whether HIV-2 has a tendency to integrate in
regions of the genome that may affect its replicative capacity
relative to that of HIV-1, we mapped HIV-2 integration sites
during in vitro infection of primary PBMCs. Previously it has
been shown that cell type-specific differences in transcription
have a modest but significant effect on HIV-1 integration tar-
geting (27). Additionally, differences in integration site selec-
tion by HIV-1 have been reported between growth-arrested
and dividing cells (9). In order to minimize bias in the inter-
pretation of our results, we used a primary HIV-2 isolate and
used primary PBMCs as the target cell type for this study.
We used a linker-mediated nested PCR approach to map
HIV-2 integration sites. This technical approach has been used
previously and has been demonstrated to effectively map ret-
roviral integration sites without significant bias (34, 41). In our
study, we used a first-round reverse viral primer that was spe-
cific to the HIV-2 gag gene, immediately downstream of the
HIV-2 5 LTR, and a second-round reverse viral primer lo-
cated near the 5 end of the viral 5 LTR. This effectively
prevented amplification of internal HIV-2 genomic fragments
primed from the 3 viral LTR. The recognition sequence for
the enzyme we selected, DraI, occurs frequently in the human
genome but is not found in the LTR of circulating strains of
HIV-2. Of concern was the possibility that the recognition
sequence for this enzyme (TTT/AAA) would favor AT-rich
regions of the genome. However, the average GC content in
the flanking 1 Mb surrounding the HIV-2 integration sites was
significantly higher than the average GC content of the human
genome, demonstrating that our approach did not significantly
bias the results towards AT-rich regions of the genome.
HIV-2 strongly favored integration within transcriptional
units. Similar integration targeting preferences have been re-
ported for HIV-1 (27, 34) as well as for SIV (10, 13). For
instance, in a recent report, Crise et al. mapped 148 SIV
integration sites in CEMx174 cells and reanalyzed data from
334 HIV-1 integrations in SupT1 cells. The frequency of inte-
grations landing within Refseq genes was 74% for SIV and
72% for HIV-1 (10). Although these proportions are slightly
less than we observed for HIV-2 (82%), differences are likely
because the above data were analyzed based on the July 2003
freeze of the human genome, and the data set of Refseq genes
would have been slightly smaller than the number currently
available for our analysis.
Within transcriptional units, HIV-2 had a preference to in-
tegrate in the reverse direction, a finding that differed from
that for HIV-1 (34). When located within transcriptional units,
human endogenous retrovirus (HERV) sequences occur more
commonly in the reverse direction of the transcript, although
this is believed to be due to selection against transcriptional
termination caused by the HERV polyadenylation sequence
(3, 37). However, the possibility remains that the direction of
proviral integration may have an effect on viral transcription
for HERVs, and similarly, proviral integration in the reverse
direction of the cellular transcript could possibly increase the
likelihood of HIV-2 establishing latent infection.
HIV-2 is now the third lentivirus (along with HIV-1 and
SIV) reported to have a strong preference towards integration
within transcriptional units. Only a slight preference towards
transcriptional units has been reported for MLV and ASLV. In
contrast to MLV and ASLV, HIV-1, HIV-2, and SIV all infect
primates as their natural hosts; it is possible that differences in
integration targeting preference by MLV and ASLV are due to
the fact that these viruses have been studied in human cells.
However, Barr et al. recently examined integration targeting by
HIV-1 and ASLV in chicken embryo fibroblasts and found
integration preferences similar to those found previously in
human cells (4). It is also possible that lentiviruses have an
integration targeting mechanism that differs from that of other
retroviruses. For instance, the p75 isoform of the transcrip-
tional coactivator lens epithelium-derived growth factor
(LEDGF/p75) is believed to promote tethering of HIV-1 in-
tegrase to DNA (38). In addition to HIV-1, LEDGF/p75 has
been shown to interact with the integrase of HIV-2 and that of
the lentivirus feline immunodeficiency virus but does not in-
teract with the integrases of human T-cell lymphotrophic virus
type 2, Moloney murine leukemia virus, and Rous sarcoma
virus (6). Additionally, HIV-1 integration within transcrip-
tional units occurs less frequently in cells that are depleted of
LEDGF/p75 than control cells (8).
HIV-2 integration was strongly favored in SINEs, and sim-
ilar preferences have been reported for HIV-1 integration
(34). In contrast, integration within LINEs and LTR elements
was disfavored by HIV-2. Areas of high gene expression in the
human genome are associated with high gene density, high GC
content, high SINE density, and low LINE density (39). These
characteristics are all consistent with preferences in integration
site targeting observed for HIV-2. This preference could pos-
sibly be explained by an interaction between the HIV-2 prein-
tegration complex and the transcription factors that are com-
monly found at these domains. Indeed, HIV-1 maintains a
TABLE 3. Proportions of HIV-1-infected and HIV-2-infected subjects
with evidence of proviral integration within heterochromatin,
based on alphoid repeat PCR
Virus
No. of alphoid repeat PCR-positive
subjects/no. of subjects tested
(P value)a
HIV-1 ..................................................................... 0/21 (0.0497)
HIV-2 ..................................................................... 5/23
a Two-sided P value for Fisher’s exact test for a difference in the proportions
of HIV-1- and HIV-2-infected subjects that showed evidence of proviral inte-
gration in heterochromatin.
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preference of integrating within actively transcribed genes (27,
34). It is also possible that these regions are favored because
they are relatively accessible, making it easier for an interac-
tion to occur between cellular DNA and the preintegration
complex.
Since only a small proportion of cells carry integrated pro-
viral DNA in vivo, studies examining retroviral integration sites
in vivo are extremely tedious and have been limited. In the
most extensive study, Han et al. mapped 74 HIV-1 integration
sites in resting CD4 T cells from 16 patients on highly active
antiretroviral therapy and found that the majority of integra-
tions were located within transcriptional units (11). Because
integration within heterochromatin results in low viral tran-
scription (16, 24), differences between HIV-1 and HIV-2 in the
proportion of proviral integrations within heterochromatin in
vivo could account for the difference in replication and patho-
genesis observed between these viruses. As an alternative to
mapping individual integration sites in vivo, we used alphoid
repeat PCR to broadly assay for evidence of proviral integra-
tion in heterochromatin in subjects infected with HIV-1 and
subjects infected with HIV-2.
We acknowledge that alphoid repeat PCR had distinct lim-
itations. Importantly, amplification was contingent on proviral
integration in relatively close proximity to alphoid repeats. The
absence of amplification does not definitively represent the
absence of integration within heterochromatin. Additionally,
although this approach allowed us to assay for a rare event
more efficiently than can be detected by integration mapping,
the overall proviral DNA copy number in vivo is relatively
small (median  87 copies/g DNA for samples used in this
study), limiting our overall ability to effectively quantify the
number of integration events in heterochromatin in vivo. It
should be noted that these limitations exist for both HIV-1 and
HIV-2 samples, yet evidence of proviral integration within
heterochromatin existed for a statistically higher proportion of
HIV-2-infected subjects than for HIV-1-infected subjects. Al-
though this observation is consistent with the notion that
HIV-2 replicates to a lesser degree than HIV-1 in vivo, this
difference was modest and cannot fully account for the sub-
stantially higher viral loads observed in HIV-1 infection.
In this study we found in vitro integration site selection for
HIV-2 to be similar to what has previously been reported for
HIV-1, yet we found a possible difference in the integration
site profile in vivo. Two possible explanations may account for
this discordance. First, it is possible that in vitro infection
studies do not properly model in vivo retroviral integration site
selection and there are cellular or physiologic factors involved
in proviral integration in vivo that are absent during in vitro
viral infection. Second, it is possible that HIV-1 and HIV-2 do
not have inherent differences in integration site selection per
se but that differences in the integration profile arise due to
selective pressures in vivo and are not captured during acute in
vitro infection. For instance, the LTRs of HIV-1 and HIV-2
contain different regulatory elements and respond differently
to cellular stimuli (12). If integration in heterochromatin were
to result in repression of transcription more effectively for
HIV-2 than for HIV-1, then the result would likely be a strong
selection against integration within heterochromatin in vivo for
HIV-1 due to cytopathic effects of viral replication and cell-
mediated immune responses against infected cells.
To our knowledge, this is the first study to examine integra-
tion site selection by HIV-2. We examined integration site
selection during in vitro infection using a primary viral isolate
to infect primary PBMCs and observed HIV-2 to have inte-
gration tendencies similar to those previously reported for
HIV-1. We observed evidence of integration in heterochroma-
tin in vivo more commonly with HIV-2-infected subjects than
with HIV-1-infected subjects. However, evidence of integra-
tion in heterochromatin occurred in only a small proportion of
HIV-2 samples. These findings suggest that the impact of in-
tegration site selection may play a small or negligible role in
the differences in pathogenesis between HIV-1 and HIV-2.
Further studies are needed to fully characterize the viral de-
terminants involved in the pathogenicity of HIV-1 and HIV-2.
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